3,919
Views
5
CrossRef citations to date
0
Altmetric
Editorial

Methotrexate for inflammatory bowel disease: time for reconsideration

ORCID Icon, &
Pages 407-409 | Received 30 Nov 2018, Accepted 14 Mar 2019, Published online: 21 Mar 2019
 

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

Reviewer disclosures

A reviewer of this manuscript has declared that they have had a working relationship with Ferring, MSD, Abbvie, Takeda, Janssen, Mylan, Pfizer, Sandoz.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.